Laws and Labels: A Regulatory View of Biosimilars

Friday, October 30, 2015
Presented by: 
Erika Lietzan

Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.

You may also like:

Blog Post

With an increasing number of diabetes patients needing care, and not enough healthcare professionals to adequately manage their chronic conditions, community pharmacists may be uniquely positioned to help fill these needs. ...

View Blog Post
Blog Post

As I write this blog, I am wrapping up participating in the annual meeting of one of my favorite organizations: The American Society of Automation in Pharmacy (ASAP). ...

View Blog Post
Blog Post

This is the last week for the public to submit comments to the Centers for Medicare & Medicaid Services (CMS) on the agency’s proposed rule, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up